Physician profile
Anthony J Rupp
NPI 1154524288
$495.74
in general payments reported to CMS, 2019-2025
15 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.16 · 2024: $72.93 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $64.44 | 2024-2025 | Jynarque |
| Travere Therapeutics, INC. | $57.94 | 2025 | |
| Calliditas Therapeutics US INC. | $54.95 | 2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $43.48 | 2025 | |
| Ardelyx, INC. | $36.92 | 2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $35.99 | 2024-2025 | Velphoro, Velphoro |
| Scpharmaceuticals INC. | $35.24 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.26 | 2025 | |
| Akebia Therapeutics INC | $29.66 | 2019 | |
| Vantive US Healthcare LLC | $23.14 | 2025 | Renal - Pd |
| Baxter Healthcare | $19.62 | 2019 | |
| Horizon Therapeutics Plc | $17.88 | 2019 | |
| Novo Nordisk INC | $16.20 | 2025 | Ozempic |
| Amgen INC. | $15.67 | 2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.35 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Rupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.